title: Update in Lung Cancer 2014.
abstract: In the past 2 years, lung cancer research and clinical care have advanced significantly. Advancements in the field have improved outcomes and promise to lead to further reductions in deaths from lung cancer, the leading cause of cancer death worldwide. These advances include identification of new molecular targets for personalized targeted therapy, validation of molecular signatures of lung cancer risk in smokers, progress in lung tumor immunotherapy, and implementation of population-based lung cancer screening with chest computed tomography in the United States. In this review, we highlight recent research in these areas and challenges for the future.
authors.affiliation: 1 Division of Computational Biomedicine, Boston University School of Medicine, Boston, Massachusetts.
authors.forename: Avrum
authors.identifier: http://orcid.org/0000-0003-1467-0489
authors.initials: A
authors.lastname: Spira
authors.affiliation: 2 Department of Medicine, Columbia University Medical Center, New York, New York; and.
authors.forename: Balazs
authors.identifier: http://orcid.org/0000-0001-7548-8360
authors.initials: B
authors.lastname: Halmos
authors.affiliation: 3 Division of Pulmonary, Critical Care, and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
authors.forename: Charles A
authors.identifier: http://orcid.org/0000-0003-3509-891X
authors.initials: CA
authors.lastname: Powell
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis; D035843:Biomedical Research; D055088:Early Detection of Cancer / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy*; D008403:Mass Screening / Q000379:methods*; D014057:Tomography, X-Ray Computed; D014481:United States
chemical_list: D014408:Biomarkers, Tumor
keywords: biomarkers; chest computed tomography screening; lung cancer; lung immunotherapy; targeted therapy